410 related articles for article (PubMed ID: 31912157)
1. Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B.
Farag MS; van Campenhout MJH; Pfefferkorn M; Fischer J; Deichsel D; Boonstra A; van Vuuren AJ; Ferenci P; Feld JJ; Berg T; Hansen BE; van Bömmel F; Janssen HLA
Clin Infect Dis; 2021 Jan; 72(2):202-211. PubMed ID: 31912157
[TBL] [Abstract][Full Text] [Related]
2. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
3. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
4. Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients.
Chen GY; Zhu MF; Zheng DL; Bao YT; Wang J; Zhou X; Lou GQ
World J Gastroenterol; 2014 Jul; 20(25):8195-200. PubMed ID: 25009392
[TBL] [Abstract][Full Text] [Related]
5. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
[TBL] [Abstract][Full Text] [Related]
6. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
Limothai U; Chuaypen N; Poovorawan K; Chotiyaputta W; Tanwandee T; Poovorawan Y; Tangkijvanich P
J Viral Hepat; 2019 Dec; 26(12):1481-1488. PubMed ID: 31446638
[TBL] [Abstract][Full Text] [Related]
7. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
Ji YJ; Li FF; Ren WH; Zhu YH; Qin CY
Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):335-9. PubMed ID: 24025132
[TBL] [Abstract][Full Text] [Related]
8. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
[TBL] [Abstract][Full Text] [Related]
9. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
Gheorghiţa VI; Caruntu FA; Curescu M; Olaru I; Radu MN; Colţan G; Streinu-Cercel A
J Gastrointestin Liver Dis; 2013 Mar; 22(1):27-32. PubMed ID: 23539387
[TBL] [Abstract][Full Text] [Related]
10. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy.
Chuaypen N; Posuwan N; Chittmittraprap S; Hirankarn N; Treeprasertsuk S; Tanaka Y; Shinkai N; Poovorawan Y; Tangkijvanich P
Clin Microbiol Infect; 2018 Mar; 24(3):306.e7-306.e13. PubMed ID: 28750917
[TBL] [Abstract][Full Text] [Related]
11. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment.
Wang X; Chi X; Wu R; Xu H; Gao X; Yu L; Liu L; Zhang M; Tan Y; Niu J; Jin Q
Virol J; 2021 Jan; 18(1):4. PubMed ID: 33407619
[TBL] [Abstract][Full Text] [Related]
12. HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B.
Zhang C; Yang Z; Wang Z; Dou X; Sheng Q; Li Y; Han C; Ding Y
Int J Med Sci; 2020; 17(3):383-389. PubMed ID: 32132873
[No Abstract] [Full Text] [Related]
13. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B.
Chuaypen N; Posuwan N; Payungporn S; Tanaka Y; Shinkai N; Poovorawan Y; Tangkijvanich P
Liver Int; 2016 Jun; 36(6):827-36. PubMed ID: 26678018
[TBL] [Abstract][Full Text] [Related]
14. Triple motif proteins 19 and 38 correlated with treatment responses and HBsAg clearance in HBeAg-negative chronic hepatitis B patients during peg-IFN-α therapy.
Luo H; Tan G; Hu X; Li Y; Lei D; Zeng Y; Qin B
Virol J; 2023 Jul; 20(1):161. PubMed ID: 37475028
[TBL] [Abstract][Full Text] [Related]
15. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
[TBL] [Abstract][Full Text] [Related]
16. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
Moucari R; Mackiewicz V; Lada O; Ripault MP; Castelnau C; Martinot-Peignoux M; Dauvergne A; Asselah T; Boyer N; Bedossa P; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
Hepatology; 2009 Apr; 49(4):1151-7. PubMed ID: 19115222
[TBL] [Abstract][Full Text] [Related]
17. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B core-related antigen levels predict pegylated interferon-α therapy response in HBeAg-positive chronic hepatitis B.
Beudeker BJ; Groothuismink ZM; de Man RA; Janssen H; van der Eijk AA; Boonstra A; Sonneveld MJ
Antivir Ther; 2020; 25(4):217-222. PubMed ID: 32744512
[TBL] [Abstract][Full Text] [Related]
19. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
Luo X; Yu JX; Xie L; Ma WJ; Wang LH
Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
[TBL] [Abstract][Full Text] [Related]
20. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
